ArticleCardiovascular research2026
A titin truncating variant linked to atrial fibrillation increases atrial profibrotic signalling and cholinergic sensitivity.
Article in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NovelBiomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
aimsTitin truncating variants (TTNtv) are a major genetic cause of dilated cardiomyopathy (DCM), accounting for approximately 25% of familial cases. Atrial fibrillation (AF) frequently occurs in DCM patients carrying TTNtv and may precede overt ventricular dysfunction, suggesting an atrial-specific disease mechanism. How TTNtv increase susceptibility to AF, particularly in the absence of established DCM, remains incompletely understood. This study aimed to define the cellular and molecular mechanisms by which a clinically relevant TTNtv predisposes to atrial arrhythmogenesis. METHODS AND
resultsWe introduced a patient-associated TTNtv (TTN c.59926+1G>A) into human induced pluripotent stem cell-derived atrial cardiomyocytes (hiPSC-CMs). TTNtv hiPSC-CMs exhibited proarrhythmic electrophysiological alterations, including increased spontaneous beating frequency, abnormal sodium channel kinetics, and heightened sensitivity to cholinergic agonists. In silico simulations demonstrated that heightened cholinergic sensitivity was sufficient to trigger AF under conditions of sinus tachycardia. RNA sequencing revealed dysregulation of sarcomere assembly and extracellular matrix pathways, and TTNtv hiPSC-CMs showed structurally shortened sarcomeres. Engineered heart tissues composed of TTNtv hiPSC-CMs co-cultured with cardiac fibroblasts demonstrated reduced contractile force and increased secretion of collagen, fibronectin-1 and TGF-β1, consistent with activation of profibrotic signalling. Together, these findings indicate that a TTNtv can cause intrinsic atrial electrical instability and promote pro-fibrotic signalling.
conclusionOur results identify atrial electrophysiological abnormalities and profibrotic remodelling as key mechanisms by which TTNtv increase AF risk, even in the absence of overt DCM. These findings support a primary atrial contribution to TTNtv-associated arrhythmogenesis and provide mechanistic insight into AF as an early clinical manifestation in carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.